Condition (MeSH)
Sepsis-Associated Encephalopathy
ClinicalTrials.gov lists 14 trials for Sepsis-Associated Encephalopathy or a narrower condition beneath it.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
14 of the 14 trials are tagged with Sepsis-Associated Encephalopathy itself; the rest are tagged with a narrower condition beneath it.
When did Sepsis-Associated Encephalopathy trials start? (10)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Not applicable
- Observational
Top of scale: 3
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 1 |
| 2024 | 1 |
| 2023 | 2 |
| 2022 | 1 |
| 2021 | 2 |
| 2020 | 1 |
| 2019 | 3 |
| 2017 | 1 |
| 2014 | 1 |
| 2012 | 1 |
No forecast is made for this condition: it averages 1.0 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: none of the 14 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Sepsis-Associated Encephalopathy trials in? (2)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Not applicable | 2 |
| Observational | 12 |
How many Sepsis-Associated Encephalopathy trials are recruiting? (7)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 1 |
| Recruiting | 1 |
| Active, not recruiting | 1 |
| Completed | 5 |
| Suspended | 1 |
Showing 5 of 7 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Sepsis-Associated Encephalopathy trials? (2)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Chinese Medical Association | 1 |
| Zagazig University | 1 |
Which drugs are being tested for Sepsis-Associated Encephalopathy? (3)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| DEXMEDETOMIDINE | 1 |
| Ulinastatin | 1 |
| Trazodone | 1 |
Interventions as named in the registry (5)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| No Interventions | 1 |
| IR (Immediate-Release) quetiapine fumarate (drug) | 1 |
| Blood draws | 1 |
| Propofol or Midazolam | 1 |
| Blood Sampling | 1 |
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which publications cover Sepsis-Associated Encephalopathy? (11)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| The Role of Ultrasonographic Assessment of Optic Nerve Sheath Diameter in Prediction of Sepsis-Associated Encephalopathy: Prospective Observational Study. | Neurocritical care | 2025 | Yes |
| Review on the Role of Mitochondrial Dysfunction in Septic Encephalopathy. | Cell biochemistry and biophysics | 2025 | Yes |
| Adjunctive Sedation with Dexmedetomidine for the Prevention of Severe Inflammation and Septic Encephalopathy: A Pilot Randomized Controlled Study. | Critical care medicine | 2025 | Yes |
| Reduced phosphatidylcholine and phosphatidylethanolamine levels correlate with inflammatory activation in sepsis-associated encephalopathy. | European journal of medical research | 2025 | Yes |
| Plasma miR-370-3P as a Biomarker of Sepsis-Associated Encephalopathy, the Transcriptomic Profiling Analysis of Microrna-Arrays From Mouse Brains. | Shock (Augusta, Ga.) | 2020 | Yes |
Showing 5 of 11 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: serious adverse events in this condition's trials, prevalence, rare-disease identity, and sub-conditions in mesh.